The association of antiphospholipid (aPL) antibodieswith thrombosisin patientswith
antiphospholipid syndrome (APS) is well documented in humans and in animal studies …

Lysophosphatidylcholine (LPC) is formed by hydrolysis of PC in low density lipoprotein
(LDL) and cell membranes by phospholipase A2 or by oxidation. Oxidized (ox) LDL …

Introduction 3. Immunology of atherosclerosis 3.1. Oxidative modification of LDL 3.2. Lesion
development and composition 3.3. Immune mechanisms in atherosclerosis 4. Antibodies in …

Diagnostic assays for antiphospholipid antibodies are routinely performed on microtitre
plates coated with cardiolipin. Here we show that contact between cardiolipin and NUNC …

β2-Glycoprotein I (β2-GPI) is a major antigen for anticardiolipin antibodies (aCL, Abs)
present in patients with antiphospholipidsyndrome (APS). We recently reported that oxidized …

Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary
artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute …

Objective To test the feasibility of applying a mimetic (specific for a patient‐derived
prothrombotic anticardiolipin antibody [aCL]) to study the homologous, disease‐associated …

Arterial or venous thrombotic events have been described as complications in patients with
positive anticardiolipin antibodies (aCL), affecting various organs including the heart. In …

Anticardiolipin antibodies (ACLAs) and the lupus anticoagulant (antiphospholipid
antibodies) are risk factors for arterial atherothrombosis and for arterial and venous …

Objective. We have recently reported that natural antibodies against phosphorylcholine (anti-
PC) have atheroprotective properties. Here we compare anti-PC with other autoantibodies in …